The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to ...

Cardinal Health's analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology rising in adoption and accessibility gains.

President Trump blared about the “GREAT JOBS NUMBERS” from last week’s jobs report. But a deeper look at the data shows the U ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and ...

Johnson & JohnsonJNJ and AbbVie ABBV are leading drugmakers with strong franchises in immunology, oncology and neuroscience.

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...

Biopharmaceutical company AbbVie plans to spend $380 million building two new manufacturing facilities in North Chicago, Illinois – a rare example of a project that’s in line with initiatives by the ...

The new drug-pricing site is designed to help uninsured Americans ...

The recent dip may have been an overreaction.

The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...

MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US MedImpact Holdings, Inc. today announced the ...